Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14556020 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL14106729 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL21539004 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL22697521 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24825613 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24824212 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL23266122 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24824209 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL20713594 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18158169 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | SICHUAN FUSHENGYUAN TECHNOLOGY CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20170008977-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9446144-B2 | Glycopeptide and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9211345-B2 | Glycopeptide and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150087806-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8980311-B2 | Liposome-mediated ligation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130236486-A1 | IMMUNOGENIC VACCINE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120039984-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7820797-B2 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090196916-A1 | Chemoselective ligation of hydrophobic reactants in a lipid phase; thioester and cysteine moieties that are involved in the ligation reaction are positioned within the lipid phase such that the ligation reaction takes place within the lipidic structure | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | CD4, STT3A, UGCG | L3MBTL1 1080/4885LGALS1 35/4885LGALS3 40/4885 |
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | L3MBTL1 1693/4885LGALS1 25/4885LGALS3 16/4885 |
| US-20090196916-A1 | Chemoselective ligation of hydrophobic reactants in a lipid phase; thioester and cysteine moieties that are involved in the ligation reaction are positioned within the lipid phase such that the ligation reaction takes place within the lipidic structure | LIPA, LYPLA1, LYPLA2 | L3MBTL1 502/4885LGALS1 2123/4885LGALS3 2533/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | L3MBTL1 490/4885LGALS1 523/4885LGALS3 563/4885 |
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | TPD52L2, F12, H1-0 | L3MBTL1 216/4885LGALS1 170/4885LGALS3 179/4885 |
| US-20170008977-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | L3MBTL1 1693/4885LGALS1 25/4885LGALS3 16/4885 |
| US-20150087806-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | L3MBTL1 1693/4885LGALS1 25/4885LGALS3 16/4885 |
| US-20120039984-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | L3MBTL1 1693/4885LGALS1 25/4885LGALS3 16/4885 |
| US-20130236486-A1 | IMMUNOGENIC VACCINE | MUC1, LGALS3BP, LGALS2 | L3MBTL1 1465/4885LGALS1 5/4885LGALS3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.